Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?
Circulation · 14.05.2024 · 149 (20) · 1598-1610
DOI: 10.1161/circulationaha.123.065880 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 14.05.2024. Verfasst von Xiaokang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics (X.C., H.W., Y.L., L.L., W.E.W.), Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing…. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Cell Proliferation. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
Defining mechanisms of cardiomyocyte proliferation should guide the understanding of endogenous cardiac regeneration and could lead to novel treatments for diseases such as myocardial infarction. In the neonatal heart, energy metabolic reprogramming (phenotypic alteration of glucose, fatty acid, and amino acid metabolism) parallels cell cycle arrest of cardiomyocytes. The metabolic reprogramming occurring shortly after birth is associated with alterations in blood oxygen levels, metabolic substrate availability, hemodynamic stress, and hormone release. In the adult heart, myocardial infarction causes metabolic reprogramming but these changes cannot stimulate sufficient cardiomyocyte proliferation to replace those lost by the ischemic injury. Some putative pro-proliferative interventions can induce the metabolic reprogramming. Recent data show that altering the metabolic enzymes PKM2 [pyruvate kinase 2], LDHA [lactate dehydrogenase A], PDK4 [pyruvate dehydrogenase kinase 4], SDH [succinate dehydrogenase], CPT1b [carnitine palmitoyl transferase 1b], or HMGCS2 [3-hydroxy-3-methylglutaryl-CoA synthase 2] is sufficient to partially reverse metabolic reprogramming and promotes adult cardiomyocyte proliferation. How metabolic reprogramming regulates cardiomyocyte proliferation is not clearly defined. The possible mechanisms involve biosynthetic pathways from the glycolysis shunts and the epigenetic regulation induced by metabolic intermediates. Metabolic manipulation could represent a new approach to stimulate cardiac regeneration; however, the efficacy of these manipulations requires optimization, and novel molecular targets need to be defined. In this review, we summarize the features, triggers, and molecular regulatory networks responsible for metabolic reprogramming and discuss the current understanding of metabolic reprogramming as a critical determinant of cardiomyocyte proliferation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Geriatrics (X.C., H.W., Y.L., L.L., W.E.W.), Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- Cardiovascular Center (X.C., H.W., Y.L., L.L., W.E.W.), Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- Independence Blue Cross Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA (S.R.H.).
ORCID-Profile: Xiaokang Chen, Hao Wu, Ya Liu, Steven R Houser, Wei Eric Wang
Zitieren
APA
Chen, X., Wu, H., Liu, Y., Liu, L., Houser, S. R., & Wang, W. E. (2024). Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?. Circulation, 149(20), 1598-1610. https://doi.org/10.1161/circulationaha.123.065880
Vancouver
Chen X, Wu H, Liu Y, Liu L, Houser SR, Wang WE. Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?. Circulation. 2024;149(20):1598-1610. doi:10.1161/circulationaha.123.065880
BibTeX
@article{Chen2024,
author = {Chen, Xiaokang and Wu, Hao and Liu, Ya and Liu, Lingyan and Houser, Steven R and Wang, Wei Eric},
title = {Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?},
journal = {Circulation},
year = {2024},
volume = {149},
number = {20},
pages = {1598--1610},
doi = {10.1161/circulationaha.123.065880}
}
EUVIMED